Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This will be a randomized, placebo-controlled, double-blind single-center proof of concept
study to evaluate the anti-EBV activity of 4 grams of valomaciclovir (2 grams BID) for 21
days in subjects with infectious mononucleosis documented to be caused by primary EBV
infection. Otherwise healthy subjects (≥15 years old) referred to us with a clinical
diagnosis of primary infectious mononucleosis will be screened and those with
laboratory-confirmed primary EBV infection will be enrolled.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute